Daichi Fujimoto

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7475456/publications.pdf

Version: 2024-02-01

42 papers	1,464 citations	489802 18 h-index	371746 37 g-index
44 all docs	44 docs citations	44 times ranked	2762 citing authors

#	Article	IF	Citations
1	A Real-World Study on the Effectiveness and Safety of Pembrolizumab Plus Chemotherapy for Nonsquamous NSCLC. JTO Clinical and Research Reports, 2022, 3, 100265.	0.6	15
2	Creation of an Integrated Clinical Trial Database and Data Sharing for Conducting New Research by the Japan Lung Cancer Society. JTO Clinical and Research Reports, 2022, 3, 100317.	0.6	1
3	Histologic transformation of epidermal growth factor receptorâ€"mutated lung cancer. European Journal of Cancer, 2022, 166, 41-50.	1.3	10
4	Alternating Therapy with Osimertinib and Afatinib for Treatment-Naive Patients with EGFR-Mutated Advanced Nonâ€"Small Cell Lung Cancer: A Single-Group, Open-Label Phase 2 Trial (WJOG10818L). Lung Cancer, 2022, 168, 38-45.	0.9	5
5	Drug-Related Pneumonitis Induced by Osimertinib as First-Line Treatment for Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell LungÂCancer. Chest, 2022, 162, 1188-1198.	0.4	11
6	Prospective multicenter cohort study of durvalumab for patients with unresectable stage III non-small cell lung cancer and grade 1 radiation pneumonitis. Lung Cancer, 2022, 171, 3-8.	0.9	3
7	Durvalumab for patients with unresectable stage III non-small cell lung cancer and grade 1 radiation pneumonitis following concurrent chemoradiotherapy: a multicenter prospective cohort study. Investigational New Drugs, 2021, 39, 853-859.	1.2	4
8	Sequential therapy of crizotinib followed by alectinib for non-small cell lung cancer harbouring anaplastic lymphoma kinase rearrangement (WJOG9516L): A multicenter retrospective cohort study. European Journal of Cancer, 2021, 145, 183-193.	1.3	15
9	Chemotherapy plus atezolizumab for a patient with small cell lung cancer undergoing haemodialysis: a case report and review of literature. Respirology Case Reports, 2021, 9, e00741.	0.3	5
10	Clinical factors associated with shorter durable response, and patterns of acquired resistance to first-line pembrolizumab monotherapy in PD-L1-positive non-small-cell lung cancer patients: a retrospective multicenter study. BMC Cancer, 2021, 21, 346.	1.1	21
11	Pembrolizumab plus chemotherapy-induced pneumonitis in chemo-naÃ¯ve patients with non-squamous non-small cell lung cancer: A multicentre, retrospective cohort study. European Journal of Cancer, 2021, 150, 63-72.	1.3	20
12	Abstract 2976: Establishment of organoids derived from patients with advanced thoracic malignancies. , 2021, , .		0
13	A Phase II Study to Assess the Efficacy of Osimertinib in Patients With EGFR Mutation-positive NSCLC Who Developed Isolated CNS Progression (T790M-negative or Unknown) During First- or Second-generation EGFR-TKI or Systemic Disease Progression (T790M-negative) After Treatment With First- or Second-generation EGFR-TKI and Platinum-based Chemotherapy (WJOG12819L). Clinical Lung Cancer, 2021, 22, 376-380.	1.1	6
14	â€œInterchangeabilityâ€•of PD-L1 immunohistochemistry assays: a meta-analysis of diagnostic accuracy. Modern Pathology, 2020, 33, 4-17.	2.9	135
15	Osimertinib in a patient with non-small cell lung cancer and renal failure undergoing hemodialysis: a case report. Investigational New Drugs, 2020, 38, 1192-1195.	1.2	8
16	Real-world effectiveness and safety of nivolumab in patients with non-small cell lung cancer: A multicenter retrospective observational study in Japan. Lung Cancer, 2020, 140, 8-18.	0.9	56
17	Nivolumab treatment of elderly Japanese patients with non-small cell lung cancer: subanalysis of a real-world retrospective observational study (CA209-9CR). ESMO Open, 2020, 5, e000656.	2.0	4
18	Differential significance of molecular subtypes which were classified into EGFR exon 19 deletion on the first line afatinib monotherapy. BMC Cancer, 2020, 20, 103.	1.1	14

#	Article	IF	Citations
19	Association Between Early Immune-related Adverse Events and Clinical Outcomes in Patients With Nonâ€"Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors. Clinical Lung Cancer, 2020, 21, e315-e328.	1.1	29
20	Efficacy and safety of pembrolizumab as first-line therapy in advanced non-small cell lung cancer with at least 50% PD-L1 positivity: a multicenter retrospective cohort study (HOPE-001). Investigational New Drugs, 2019, 37, 1266-1273.	1.2	38
21	Nivolumab for advanced non-small cell lung cancer patients with mild idiopathic interstitial pneumonia: A multicenter, open-label single-arm phase II trial. Lung Cancer, 2019, 134, 274-278.	0.9	62
22	Ineligibility for the PACIFIC trial in unresectable stage III non-small cell lung cancer patients. Cancer Chemotherapy and Pharmacology, 2019, 84, 275-280.	1.1	18
23	Association Between Formalin Fixation Time and Programmed Cell Death Ligand 1 Expression in Patients With Non-Small Cell Lung Cancer. Anticancer Research, 2019, 39, 2561-2567.	0.5	3
24	A phase II study of low starting dose of afatinib as first-line treatment in patients with EGFR mutation-positive non-small-cell lung cancer (KTORG1402). Lung Cancer, 2019, 135, 175-180.	0.9	24
25	Early depth of tumor shrinkage and treatment outcomes in non-small cell lung cancer treated using Nivolumab. Investigational New Drugs, 2019, 37, 1257-1265.	1.2	10
26	Clinical significance of monitoring EGFR mutation in plasma using multiplexed digital PCR in EGFR mutated patients treated with afatinib (West Japan Oncology Group 8114LTR study). Lung Cancer, 2019, 131, 128-133.	0.9	18
27	Pseudoprogression in Previously Treated Patients with Nonâ€"Small Cell Lung Cancer Who Received Nivolumab Monotherapy. Journal of Thoracic Oncology, 2019, 14, 468-474.	0.5	81
28	Efficacy and safety of nivolumab in previously treated patients with non-small cell lung cancer: A multicenter retrospective cohort study. Lung Cancer, 2018, 119, 14-20.	0.9	115
29	Predictive Performance of Four Programmed CellÂDeath Ligand 1 Assay Systems on Nivolumab Response in Previously Treated Patients with Nonâ€"Small Cell Lung Cancer. Journal of Thoracic Oncology, 2018, 13, 377-386.	0.5	50
30	Successful oral desensitization with osimertinib following osimertinib-induced fever and hepatotoxicity: a case report. Investigational New Drugs, 2018, 36, 952-954.	1.2	13
31	Concordance between the response evaluation criteria in solid tumors version 1.1 and the immune-related response criteria in patients with non-small cell lung cancer treated with nivolumab: a multicenter retrospective cohort study. Cancer Chemotherapy and Pharmacology, 2018, 81, 333-337.	1.1	8
32	Comparison of PD-L1 Assays in Non-small Cell Lung Cancer: 22C3 pharmDx and SP263. Anticancer Research, 2018, 38, 6891-6895.	0.5	18
33	Clinical Characteristics and Prognosis of Patients With Advanced Nonâ€"Small-cell Lung Cancer Who Are Ineligible for Clinical Trials. Clinical Lung Cancer, 2018, 19, e721-e734.	1.1	30
34	Programmed Cell Death Ligand 1 Expression in Nonâ€"Small-cell Lung Cancer Patients With Interstitial Lung Disease: A Matched Case-controlÂStudy. Clinical Lung Cancer, 2018, 19, e667-e673.	1.1	9
35	Natural history and clinical characteristics of multiple pulmonary nodules with ground glass opacity. Respirology, 2017, 22, 1615-1621.	1.3	29
36	Early Immune-Related Adverse Events and Association with Outcome in Advanced Nonâ€"Small Cell Lung Cancer Patients Treated with Nivolumab: AÂProspective Cohort Study. Journal of Thoracic Oncology, 2017, 12, 1798-1805.	0.5	311

#	Article	IF	Citations
37	Alteration of PD-L1 expression and its prognostic impact after concurrent chemoradiation therapy in non-small cell lung cancer patients. Scientific Reports, 2017, 7, 11373.	1.6	70
38	A pilot trial of nivolumab treatment for advanced non-small cell lung cancer patients with mild idiopathic interstitial pneumonia. Lung Cancer, 2017, 111, 1-5.	0.9	65
39	Characteristics and Prognostic Impact of Pneumonitis during Systemic Anti-Cancer Therapy in Patients with Advanced Non-Small-Cell Lung Cancer. PLoS ONE, 2016, 11, e0168465.	1.1	52
40	The safety and efficacy of paclitaxel and carboplatin with or without bevacizumab for treating patients with advanced nonsquamous non-small cell lung cancer with interstitial lung disease. Cancer Chemotherapy and Pharmacology, 2014, 74, 1159-1166.	1.1	49
41	Comparison of two transport systems available in Japan (TERUMO kenkiporter II and BBL Port-A-Cul) for maintenance of aerobic and anaerobic bacteria. Journal of Infection and Chemotherapy, 2014, 20, 26-29.	0.8	1
42	Preexisting interstitial lung disease is inversely correlated to tumor epidermal growth factor receptor mutation in patients with lung adenocarcinoma. Lung Cancer, 2013, 80, 159-164.	0.9	28